114 results about "CD3 Antibody" patented technology

The invention discloses a bifunctional T cell adapter targeting CD14 and CD3 and an application of the bifunctional T cell adapter. Specifically, the invention provides a CD14 and CD3 targeting bifunctional T cell adapter, the CD14 and CD3 targeting bifunctional T cell adapter comprises a skeleton containing an IgG antibody constant region, the skeleton comprises two heavy chains and a light chain, one heavy chain comprises heavy chain constant regions CH1, CH2 and CH3, the other heavy chain comprises CH2 and CH3, the light chain comprises CL, the CD14 and CD3 targeting bifunctional T cell adapter is a heterotrimer, and the CD14 and CD3 targeting bifunctional T cell adapter is a heterotrimer. Specifically, the first subunit comprises a light chain variable region of an anti-CD14 antibody and a light chain in the skeleton, the second subunit comprises a heavy chain variable region of the anti-CD14 antibody and a heavy chain in the skeleton, and the third subunit comprises a heavy chain variable region of an anti-CD3 antibody and a light chain variable region. The bifunctional T cell adapter disclosed by the invention has an excellent tumor killing effect.

The present application relates to an anti-CD3 antibody and its application. The present application develops a specific antibody molecule targeting CD3 epsilon chain, which can activate T cells by combining with CD3 epsilon on T cells. A T cell binding protein containing the CD3 antibody is further designed, which can specifically target and bind to CD3 epsilon on the surface of T cells in vivo and in vitro, so as to achieve moderate activation of T cells. The CAR lentivirus containing the T cell binding protein of the present application can induce the generation of CAR-T cells in vitro and in vivo, and the CAR-T cells have good tumor cell killing efficiency.

The application discloses an antibody targeting DLL3 and application thereof, and relates to the field of biological medicines. Specific anti-DLL3 nanobodies are screened in the embodiment of the application, and a bispecific antibody constructed from the anti-human DLL3 nanobody or humanized nanobody and an anti-human CD3 antibody is prepared, the obtained bispecific antibody has good antitumor activity, can be applied to preparation of at least one drug for preventing or treating a DLL3 expression abnormality related tumor or cancer disease including small cell lung cancer, and has wide application.

The present disclosure provides anti-CD3 monoclonal antibodies and related compositions, which can be used in any of a variety of therapeutic and diagnostic methods for the treatment of diseases and disorders, such as cancer and autoimmune diseases and disorders. The present disclosure also relates to bispecific antibodies comprising anti-CD3 antibodies. The present disclosure further relates to methods of treatment using such anti-CD3 monoclonal and bispecific antibodies. The present disclosure generally relates to anti-CD3 antibodies, compositions and methods using same.

The application belongs to the technical field of biological medicine, and discloses an in-situ vaccine type mRNA-tLNP preparation for solid tumor treatment and preparation and application thereof. The preparation is designed by double targets, so that CAR-T kills more tumor cells to overcome tumor heterogeneity, changes the tumor immune microenvironment through autocrine fusion proteins (anti-PD-1 scFv and TGFbetaRII, IL-15 and Flt3L, CD40L), promotes T cell proliferation, and recruits and activates dendritic cells, cross-presents new antigens in the tumor local part, and produces in-situ vaccination effects; circular RNA encoding the above proteins is prepared, and the circular RNA is wrapped by lipid nanoparticles modified by CD3 antibodies, so as to be directly delivered to the body, and a significant solid tumor treatment effect is produced.

A platform for therapy provides a multi-target therapeutic molecule comprising an anti-CD3 antigen binding fragment of an anti-CD3 antibody linked with a linker to two or more auto-antigen(s). The auto-antigens include Dsg1, Dsg3, bullous pemphigoid antigen 180, bullous pemphigoid antigen 230, MuSK, anti-phospholipase A2 Receptor. A pharmaceutical composition comprises a disclosed multi-target therapeutic molecule is disclosed. Methods of treating diseases using the disclosed molecules are disclosed

The invention discloses a pharmaceutical composition and application thereof, the pharmaceutical composition comprises a recombinant protein and an HIV virus invasion inhibitor, and the recombinant protein comprises: 1) an scFV of an anti-CD3 antibody; and 2) diphtheria toxin.

The invention discloses a recombinant oncolytic influenza virus for delivering an anti-gpA33 * CD3 bispecific antibody and application of the recombinant oncolytic influenza virus. Belongs to the technical field of biological medicine. According to the recombinant oncolytic influenza virus provided by the invention, a heavy chain variable region and a light chain variable region of an anti-gpA33 antibody and an anti-CD3 antibody are inserted into an influenza virus genome, the recombinant oncolytic influenza virus is rescued through a reverse genetics technology, and the virus can stably express an anti-gpA33 * CD3 bispecific antibody in colorectal cancer cells; one end of the antibody can be specifically combined with CD3 molecules on the surfaces of the T cells to efficiently activate the T cells, the other end of the antibody can be specifically combined with biomarker molecules gpA33 on the surfaces of the colorectal cancer cells, and under the bridging action of the antibody, the activated T cells are collected to the surfaces of the colorectal cancer cells to induce the T cells to directly generate the effect of targeted killing of the colorectal cancer cells, so that the colorectal cancer cells are efficiently killed. Therefore, the purpose of treating tumors is achieved.

This invention relates to the selective removal of activated T cells using a monovalent antibody or its antigen-binding fragment, which includes heavy chain variable regions and light chain variable regions of an antibody that specifically binds to CD3. In one embodiment of the present invention, the monovalent anti-CD3 antibody or its antigen-binding fragment is useful as a T cell removal agent or T cell immunosuppressant because it can selectively remove only activated T cells without affecting non-activated T cells. In particular, this invention is useful for the prevention or treatment of T cell-mediated autoimmune diseases, graft-versus-host diseases, or organ transplant rejection, as well as for the prevention of graft-versus-host disease (GVHD) side effects in allogeneic CAR-T cell therapy.

The present disclosure provides methods of treating a SMARCB1-deficient cancer. In certain embodiments, the methods comprise administering an anti-MUC16 / anti-CD3 antibody or antigen-binding fragment thereof to a subject in need thereof. In certain embodiments, the methods further comprise administering a PD-1 inhibitor (e.g., an anti-PD-1 antibody) or a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody) to the subject in need thereof.

The present invention provides methods of treating and preventing symptoms of coronavirus infection using antibodies that recognize CD3. The present invention further provides routes of administration and formulations for use in the methods.

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

This disclosure provides methods for treating endometrial cancer, reducing its severity, or inhibiting its growth. The methods of this disclosure comprise administering to a subject in need a single therapeutically effective amount of a bispecific antibody that specifically binds to mucin 16 (MUC16) and CD3, or administering said bispecific antibody in combination with a therapeutically effective amount of an antibody specifically binding to the programmed death 1 (PD-1) receptor or an antigen-binding fragment thereof.

The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody.The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.

The invention discloses a CD3 antibody-polypeptide, which is characterized in that an amino acid sequence of a light chain variable region of a CD3 antibody is linked with an amino acid sequence of polypeptide through a triple link of a GGGGS flexible joint; and the CD3 antibody-polypeptide can be coupled with the RNP compound through a chemical bond to form the CD3 antibody-polypeptide-RNP compound. The CD3 antibody-polypeptide-RNP compound is used as a delivery system for gene editing in the TILs cells, in the gene editing process, CD3 antibody-polypeptide has good cell penetrability and stability, an exogenous gene can be efficiently and accurately delivered into a double-chain incision manufactured on a TRAC gene of the TILs cells, cell damage caused by electrotransfection is avoided, and the CD3 antibody-polypeptide-RNP compound can be applied to gene editing of the TILs cells. The prepared TI Ls cells have a higher proportion of memory T cells (CD45RO < + > CD62L < + >) and a higher proportion of tumor specific T cells (CD8 < + >), so that the TI Ls cells have a better tumor killing effect.

Provided herein are aqueous pharmaceutical compositions containing formulations of bispecific GPRC5D / CD3 antibodies or antigen-binding fragments thereof, and methods for preparing the same. Also provided herein are methods for treating cancer in a subject in need thereof by administering to the subject the aqueous pharmaceutical compositions disclosed herein. Further provided herein are kits and articles of manufacture containing the aqueous pharmaceutical compositions disclosed herein.

The present disclosure relates to generally to methods of ameliorating or treating the neurological effects of microglial activation and methods of ameliorating or treating specific diseases that affect the central nervous system (CNS) by administering an anti-CD3 antibody in combination with a GLP-1 agonist.

The present invention relates to treating human immunodeficiency virus (HIV) infection in a subject. The subject may be administered a composition comprising a heterodimeric TCR-anti-CD3 antibody fusion molecule in a maintenance dose comprising at least 40 µg of the TCR-anti-CD3 antibody fusion molecule.

This invention discloses an in-situ constructed FAP-targeting CAR-T nanoliposome delivery system, its preparation method, and its applications, belonging to the field of biomedical technology. This invention provides a biocompatible nanoliposome delivery system whose surface is modified with a CD3 antibody that can capture T cells through circulation, delivering plasmid DNA encoding FAP-CAR into the T cells, thus in-situ transforming T cells into CAR-T cells in vivo. The nanoliposome delivery system provided by this invention can significantly alleviate myocardial fibrosis caused by myocardial infarction and restore cardiac function, providing a research basis for the clinical application of CAR-T cell therapy based on in-situ nanoengineering in myocardial infarction.

To provide anti- CD3 antibodies that more closely mimic TCR / MHC interactions and are desirable for minimizing the release of toxic cytokines while maintaining effective tumor cytolysis.SOLUTION: Novel human CD3 antigen binding polypeptides and their preparation and their use in the treatment and / or diagnosis of various diseases, as well as bispecific antibody molecules capable of activating immune effector cells and their use in the diagnosis and / or treatment of various diseases. In some embodiments, the anti-CD3 antibody is characterized or selected to have a reduced tendency to induce cytokine release upon binding to a competent T cell, e.g., due to the release of IL-2 and IFN γ.SELECTED DRAWING: Figure 1

Provided in the present application are a tumor-infiltrating lymphocyte and a culture method therefor, a culture medium, a related reagent combination, a pharmaceutical composition, and a pharmaceutical use. The culture method comprises: in an initial culture stage, adding a stimulating factor combination of IL-2, an anti-CD3 antibody, and an anti-4-1BB antibody, so as to achieve activation and expansion of the tumor-infiltrating lymphocyte, and the amount of IL-2 used can be controlled.

A modified immune cell that does not express a T-cell receptor (TCR) and comprises a CD3 antibody receptor complex. Also relates to a pharmaceutical composition comprising said modified immune cell and a bispecific antibody, and the use of said pharmaceutical composition in the preparation of a medicament.

The invention discloses an antibody combination for typing CD123 + dendritic cells and application of the antibody combination. An antibody in the antibody combination consists of a CD45 antibody, a CD3 antibody, a CD20 antibody, a CD16 antibody, an HLA-DR antibody and a CD123 antibody. When the kit formed by the antibody combination provided by the invention is used for typing the CD123 + dendritic cells in the peripheral blood single cells, the quantity and the stability of the collected cells are remarkably improved.

The invention discloses a composition for efficiently amplifying high-purity NK cells and application of a kit, and relates to the technical field of cell culture. The antibody combination comprises a CD3 antibody, a CD16 antibody and an NKG2D antibody, wherein the mass ratio of the CD3 antibody to the CD16 antibody to the NKG2D antibody is (0.01-1): (2-8): (2-8). According to the composition for activating the NK cells, provided by the invention, the PBMC cells are cultured by using the composition, so that the purity and the number of the harvested NK cells can be greatly improved, the activity of the obtained NK cells is higher, and the motility rate can reach 90% or above. Therefore, the problems of low amplification purity and few amplification times of the NK cells are solved. In addition, the NK cell amplification method provided by the invention is simple and easy to implement, and is easy to popularize and apply.

The application discloses a CD3 antibody and application thereof, and relates to the technical field of biological medicine.The antibody provided by the application is a full human antibody, which fundamentally reduces immunogenicity risk, and lays a material foundation for developing safer T cell redirection therapy.The antibody has cross-reactivity with cynomolgus monkey CD3, can be directly used for a cynomolgus monkey model to perform systematic pharmacodynamics, pharmacokinetics and safety evaluation, greatly improves the prediction value of preclinical data, and accelerates the conversion process of a candidate molecule to clinical research.

Provided herein are compositions and methods for treating spinal cord injury using nasal administration of anti-CD3 antibodies, e.g., foralumab.

The application discloses an aerosol inhalation type LNP composition for treating lung diseases and a preparation method and application thereof. The composition comprises an aerosol stabilizer and a surface coupled Anti-CD3 antibody lipid nanoparticle, and the surface coupled Anti-CD3 antibody lipid nanoparticle internally loads a CAR-mRNA targeting FAP. The application improves the efficiency of LNP targeted binding to T cells by coupling CD3 antibodies to LNP, and the LNP can significantly improve the in-vivo reprogramming efficiency of mouse T cells by coupling CD3 antibodies. The application administers the antibody coupled LNP by aerosol inhalation, and compared with common intravenous injection, the lung lesion accumulation of the LNP is improved, so that the treatment effect of pulmonary fibrosis is effectively improved.

Provided herein are aqueous pharmaceutical compositions comprising a high concentration formulation of a bispecific BCMA / CD3 antibody or antigen-binding fragment thereof, and methods of making the same. Also provided herein are methods of treating cancer in a subject by administering these aqueous pharmaceutical compositions to the subject in need thereof.

The invention belongs to the technical field of medical biological diagnosis, and relates to an application of an antibody combination in a medium-high risk myelodysplastic syndrome diagnostic kit. The eight kinds of fluorescence labeled antibodies are as follows: a PerCP-cy5.5 anti-human CD4 antibody, a KO anti-human CD45 antibody, an APC-H7 anti-human CD3 antibody, an APC anti-human PD-1 antibody, a PB anti-human CXCR5 antibody, a PC7 anti-human CD19 antibody, a PerCP-cy5.5 anti-human CD27 antibody and an FITC anti-human IgD antibody. The proportions of the four cell subpopulations in marrow of the MDS patient can be detected through the antibody composition, and the antibody composition can help clinically, rapidly and efficiently screen medium and high-risk MDS patients and guide subsequent treatment selection of the patients.

The application discloses an anti-CEACAM5 nanobody and related application thereof, and relates to the field of antibodies. The anti-CEACAM5 nanobody comprises CDR1, CDR2 and CDR3 with amino acid sequences as shown in SEQ ID NO: 1-3 or 5-7 in sequence, can specifically bind to a CEACAM5 antigen, and has an affinity of 10 ‑9 KD or above, and belongs to a high-affinity nanobody. In addition, the application constructs a bispecific antibody by combining the nanobody targeting CEACAM5 and an anti-CD3 antibody OKT3, and experiments in vitro prove that the prepared specific antibody has strong killing activity on tumor cells expressing CEACAM5, thereby providing key materials for subsequent development of immunotherapy with high-efficiency and long-lasting anti-tumor activity.